Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
about
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancerContinuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience.Recent development of targeted approaches for the treatment of breast cancer.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2(+) mammary cancer.Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models.Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients.Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
P2860
Q33430735-1B668647-BBC5-420F-AB73-0FB094F1843AQ36653094-636B75BA-A2A8-4C77-B5AB-550C661C6110Q37131686-6DDCE0B0-18E7-4A7C-966D-E13FE44994CCQ38802191-EA70EFCF-08B5-4352-B98C-CC3673458934Q38852051-D643D456-DF91-46A0-B63E-3546DD85292CQ38888368-3A981865-19FA-4ADA-B2F6-AC19A6FA12BEQ39933767-B9945D2B-812E-4781-8610-B2FBBB68C8E2Q47270020-854D2BD4-1463-47FA-A173-6356FF70245BQ48099690-912DFD10-8563-43A1-8D90-7D42CE781674Q49885166-99683EAF-209A-42E7-8002-B56674810F5AQ55412024-6D6D0630-28E8-4317-9D79-BD31314B475A
P2860
Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Ado-trastuzumab emtansine (T-D ...... vidence and clinical potential
@ast
Ado-trastuzumab emtansine (T-D ...... vidence and clinical potential
@en
Ado-trastuzumab emtansine
@nl
type
label
Ado-trastuzumab emtansine (T-D ...... vidence and clinical potential
@ast
Ado-trastuzumab emtansine (T-D ...... vidence and clinical potential
@en
Ado-trastuzumab emtansine
@nl
prefLabel
Ado-trastuzumab emtansine (T-D ...... vidence and clinical potential
@ast
Ado-trastuzumab emtansine (T-D ...... vidence and clinical potential
@en
Ado-trastuzumab emtansine
@nl
P2860
P356
P1476
Ado-trastuzumab emtansine (T-D ...... vidence and clinical potential
@en
P2093
Parvin F Peddi
Sara A Hurvitz
P2860
P304
P356
10.1177/1758834014539183
P577
2014-09-01T00:00:00Z